231 related articles for article (PubMed ID: 38455340)
1. Adipocytokines as Predictors of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Development in Type 2 Diabetes Mellitus Patients.
Fajkić A; Jahić R; Hadžović-Džuvo A; Lepara O
Cureus; 2024 Mar; 16(3):e55673. PubMed ID: 38455340
[TBL] [Abstract][Full Text] [Related]
2. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
[TBL] [Abstract][Full Text] [Related]
3. Triglyceride to HDL Cholesterol Ratio for the Identification of MASLD in Obesity: A Liver Biopsy-Based Case-Control Study.
Martínez-Montoro JI; Martínez-Sánchez MA; Balaguer-Román A; Fernández-Ruiz VE; Hernández-Barceló JE; Ferrer-Gómez M; Frutos MD; Núñez-Sánchez MÁ; Fernández-García JC; Ramos-Molina B
Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732557
[TBL] [Abstract][Full Text] [Related]
4. Novel adiponectin-resistin (AR) and insulin resistance (IRAR) indexes are useful integrated diagnostic biomarkers for insulin resistance, type 2 diabetes and metabolic syndrome: a case control study.
Lau CH; Muniandy S
Cardiovasc Diabetol; 2011 Jan; 10():8. PubMed ID: 21251282
[TBL] [Abstract][Full Text] [Related]
5. Effect of essential phospholipids on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity: study protocol of a randomized, double-blind, phase IV clinical trial.
Stefan N; Hartleb M; Popovic B; Varona R
Trials; 2024 Jun; 25(1):374. PubMed ID: 38858768
[TBL] [Abstract][Full Text] [Related]
6. Circulating Levels of Adipocytokines as Potential Biomarkers for Early Detection of Colorectal Carcinoma in Egyptian Patients.
Zekri AR; Bakr YM; Ezzat MM; Zakaria MS; Elbaz TM
Asian Pac J Cancer Prev; 2015; 16(16):6923-8. PubMed ID: 26514469
[TBL] [Abstract][Full Text] [Related]
7. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
[TBL] [Abstract][Full Text] [Related]
8. Machine learning identification of risk factors for heart failure in patients with diabetes mellitus with metabolic dysfunction associated steatotic liver disease (MASLD): the Silesia Diabetes-Heart Project.
Nabrdalik K; Kwiendacz H; Irlik K; Hendel M; Drożdż K; Wijata AM; Nalepa J; Janota O; Wójcik W; Gumprecht J; Lip GYH
Cardiovasc Diabetol; 2023 Nov; 22(1):318. PubMed ID: 37985994
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory markers as diagnostic and precision nutrition tools for metabolic dysfunction-associated steatotic liver disease: Results from the Fatty Liver in Obesity trial.
Mogna-Peláez P; Riezu-Boj JI; Milagro FI; Herrero JI; Elorz M; Benito-Boillos A; Tobaruela-Resola AL; Tur JA; Martínez JA; Abete I; Zulet MA
Clin Nutr; 2024 Jul; 43(7):1770-1781. PubMed ID: 38861890
[TBL] [Abstract][Full Text] [Related]
10. Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease.
Mak AL; Wassenaar N; van Dijk AM; Troelstra M; Houttu V; van Son K; Driessen S; Zwirs D; van den Berg-Faay S; Shumbayawonda E; Runge J; Doukas M; Verheij J; Beuers U; Nieuwdorp M; Cahen DL; Nederveen A; Gurney-Champion O; Holleboom A
JHEP Rep; 2024 Mar; 6(3):100998. PubMed ID: 38379586
[TBL] [Abstract][Full Text] [Related]
11. Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population.
Chew NWS; Pan XH; Chong B; Chandramouli C; Muthiah M; Lam CSP
Diabetes Res Clin Pract; 2024 May; 211():111652. PubMed ID: 38574897
[TBL] [Abstract][Full Text] [Related]
12. Associations between serum ferritin baselines and trajectories and the incidence of metabolic dysfunction-associated steatotic liver disease: a prospective cohort study.
Song Z; Miao X; Xie X; Tang G; Deng J; Hu M; Liu S; Leng S
Lipids Health Dis; 2024 May; 23(1):141. PubMed ID: 38760825
[TBL] [Abstract][Full Text] [Related]
13. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.
Kjærgaard K; Daugaard Mikkelsen AC; Landau AM; Eriksen PL; Hamilton-Dutoit S; Magnusson NE; Thomsen MB; Chen F; Vilstrup H; Mookerjee RP; Bay-Richter C; Thomsen KL
JHEP Rep; 2024 Mar; 6(3):100992. PubMed ID: 38415019
[TBL] [Abstract][Full Text] [Related]
14. Machine learning identifies metabolic dysfunction associated steatotic liver disease in patients with diabetes mellitus.
Nabrdalik K; Kwiendacz H; Irlik K; Hendel M; Drożdż K; Wijata AM; Nalepa J; Janota O; Wójcik W; Gumprecht J; Lip GYH
J Clin Endocrinol Metab; 2024 Feb; ():. PubMed ID: 38330228
[TBL] [Abstract][Full Text] [Related]
15. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive Indices of MASLD Are Associated With Hypogonadism in Male Patients With Type 2 Diabetes Mellitus.
Caretta N; Scafa R; Graziani A; Crepaldi MC; Vedovato M; Avogaro A; Ferlin A
J Clin Endocrinol Metab; 2024 Jan; 109(2):e522-e530. PubMed ID: 37795977
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.
Qi X; Li J; Caussy C; Teng GJ; Loomba R
Hepatology; 2024 May; ():. PubMed ID: 38722246
[TBL] [Abstract][Full Text] [Related]
18. Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups.
Fukuda T; Okamoto T; Fukaishi T; Kawakami A; Tanaka M; Yamada T; Monzen K
Front Endocrinol (Lausanne); 2024; 15():1392280. PubMed ID: 38779448
[TBL] [Abstract][Full Text] [Related]
19. Fatty Liver Index (FLI) is the best score to predict MASLD with 50% lower cut-off value in women than in men.
Crudele L; De Matteis C; Novielli F; Di Buduo E; Petruzzelli S; De Giorgi A; Antonica G; Berardi E; Moschetta A
Biol Sex Differ; 2024 May; 15(1):43. PubMed ID: 38760802
[TBL] [Abstract][Full Text] [Related]
20. Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus.
Forlano R; Martinez-Gili L; Takis P; Miguens-Blanco J; Liu T; Triantafyllou E; Skinner C; Loomba R; Thursz M; Marchesi JR; Mullish BH; Manousou P
Gut Microbes; 2024; 16(1):2304157. PubMed ID: 38235661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
